LENZ Therapeutics and Laboratoires Théa Partner to Commercialize LNZ100 for Presbyopia in Canada

LENZ Therapeutics and Laboratoires Théa have announced a license and commercialization agreement under which Théa will register and commercialize LNZ100 for the treatment of presbyopia in Canada.

Regulatory Progress in the United States

In October 2024, LENZ Therapeutics announced that the US Food and Drug Administration (FDA) had accepted its new drug application for LNZ100 to treat patients with presbyopia. Subsequently, in March 2025, the FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ plans to commence commercial launch activities in the US immediately following a potential FDA approval.

Details of the Agreement with Théa

Under the terms of this agreement, LENZ will be eligible to receive over $70 million in up-front, regulatory, and commercial milestone payments. Additionally, the agreement includes tiered, double-digit royalties on net sales. Laboratoires Théa will hold exclusive rights to develop, manufacture, register, and commercialize LNZ100 for the treatment of presbyopia patients in Canada.

Eef Schimmelpennink, President and CEO of LENZ Therapeutics, highlighted the strategic importance of this collaboration:

“Théa is a leading company in eye care in key markets around the world and was a natural choice for LENZ when looking for a highly capable commercial partner in Canada. With its strong position in commercializing eye drops, Théa is uniquely positioned to bring the benefits of LNZ100 to patients in this key market. This agreement represents our third commercialization partnership outside the United States for LNZ100, as we continue to be focused on maximizing patient access to this important therapy worldwide.”